Reversible cardiotoxicity with tyrosine kinase inhibitors.

Jawad Francis, MD,1 Manmeet S. Ahluwalia, MD,2 Meir Wetzler, MD,2 Eunice Wang, MD,2 Pamela Paplham, RN, FNP,2 Shannon Smiley, MD,2 Philip L. McCarthy, MD,2 I. Larry Cohen, MD,3 Edward Spangenthal, MD,2 and Minoo Battiwalla, MD2 1Department of Medicine, State University of New York at Buffalo, Buffalo, New York; 2Department of Medicine, 3Department of Anesthesiology and Pain Medicine, Roswell Park Cancer Institute, Buffalo, New York